Literature DB >> 32203094

Telomere length alterations and ATRX/DAXX loss in pituitary adenomas.

Christopher M Heaphy1,2,3,4, Wenya Linda Bi5,6, Shannon Coy7, Christine Davis8, Gary L Gallia9,10,11,12, Sandro Santagata7, Fausto J Rodriguez8,10.   

Abstract

Telomeres are nucleoprotein complexes located at the termini of eukaryotic chromosomes that prevent exonucleolytic degradation and end-to-end chromosomal fusions. Cancers often have critically shortened, dysfunctional telomeres contributing to genomic instability. Telomere shortening has been reported in a wide range of precancerous lesions and invasive carcinomas. However, the role of telomere alterations, including the presence of alternative lengthening of telomeres (ALT), has not been studied in pituitary adenomas. Telomere length and the presence of ALT were assessed directly at the single cell level using a telomere-specific fluorescence in situ hybridization assay in tissue microarrays. Tumors were characterized as either ALT-positive or having short, normal, or long telomere lengths and then these categories were compared with clinicopathological characteristics. ATRX and DAXX expression was studied through immunohistochemistry. We characterized a discovery set of 106 pituitary adenomas including both functional and nonfunctional subsets (88 primary, 18 recurrent). Telomere lengths were estimated and we observed 64 (59.4%) cases with short, 39 (36.8%) cases with normal, and 0 (0%) cases with long telomeres. We did not observe significant differences in the clinicopathological characteristics of the group with abnormally shortened telomeres compared to the group with normal telomeres. However, three pituitary adenomas were identified as ALT-positive of which two were recurrent tumors. Two of these three ALT-positive cases had alterations in either of the chromatin remodeling proteins, ATRX and DAXX, which are routinely altered in other ALT-positive tumor subtypes. In a second cohort of 32 recurrent pituitary adenomas from 22 patients, we found that the tumors from 36% of patients (n = 8) were ALT-positive. This study demonstrates that short telomere lengths are prevalent in pituitary adenomas and that ALT-positive pituitary adenomas are enriched in recurrent disease.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32203094      PMCID: PMC8867890          DOI: 10.1038/s41379-020-0523-2

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  3 in total

1.  Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.

Authors:  Hiba Alzoubi; Simone Minasi; Francesca Gianno; Manila Antonelli; Francesca Belardinilli; Felice Giangaspero; Marie-Lise Jaffrain-Rea; Francesca Romana Buttarelli
Journal:  Endocr Pathol       Date:  2022-01-06       Impact factor: 3.943

2.  Epigenetic Regulation of TET1-SP1 During Spermatogonia Self-Renewal and Proliferation.

Authors:  Lingling Liu; Jin Wang; Shenghua Wang; Mudi Wang; Yuanhua Chen; Liming Zheng
Journal:  Front Physiol       Date:  2022-02-11       Impact factor: 4.566

3.  Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.

Authors:  Olivera Casar-Borota; Henning Bünsow Boldt; Britt Edén Engström; Marianne Skovsager Andersen; Bertrand Baussart; Daniel Bengtsson; Katarina Berinder; Bertil Ekman; Ulla Feldt-Rasmussen; Charlotte Höybye; Jens Otto L Jørgensen; Anders Jensen Kolnes; Márta Korbonits; Åse Krogh Rasmussen; John R Lindsay; Paul Benjamin Loughrey; Dominique Maiter; Emilija Manojlovic-Gacic; Jens Pahnke; Pietro Luigi Poliani; Vera Popovic; Oskar Ragnarsson; Camilla Schalin-Jäntti; David Scheie; Miklós Tóth; Chiara Villa; Martin Wirenfeldt; Jacek Kunicki; Pia Burman
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.